SPRO Logo

Spero Therapeutics, Inc. (SPRO) 

NASDAQ
Market Cap
$64.33M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
722 of 774
Rank in Industry
398 of 432

Largest Insider Buys in Sector

SPRO Stock Price History Chart

SPRO Stock Performance

About Spero Therapeutics, Inc.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, …

Insider Activity of Spero Therapeutics, Inc.

Over the last 12 months, insiders at Spero Therapeutics, Inc. have bought $0 and sold $428,388 worth of Spero Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Spero Therapeutics, Inc. have bought $11.07M and sold $3.5M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 39,727 shares for transaction amount of $207,971 was made by Aquilo Capital, L.P. () on 2022‑04‑26.

List of Insider Buy and Sell Transactions, Spero Therapeutics, Inc.

2024-11-08SaleCFO & CBO
17,245
0.0314%
$1.30$22,419-0.76%
2024-11-07SaleCFO & CBO
23,351
0.0429%
$1.31$30,590+0.38%
2024-08-27SaleCEO & President
2,757
0.005%
$1.35$3,722-5.07%
2024-08-27Saledirector
5,912
0.0107%
$1.35$7,981-5.07%
2024-08-27SaleChief Operating Officer
2,213
0.004%
$1.35$2,988-5.07%
2024-08-05SaleCEO and President
17,641
0.0319%
$1.31$23,110-2.24%
2024-08-02SaleCEO and President
14,800
0.0276%
$1.32$19,5360.00%
2024-02-05SaleCEO and President
45,093
0.0786%
$1.45$65,385-1.39%
2024-02-02SaleCEO and President
30,901
0.0509%
$1.37$42,334-2.74%
2024-02-02SaleChief Medical Officer
28,075
0.0462%
$1.37$38,463-2.74%
2024-02-02Saledirector
63,795
0.105%
$1.37$87,399-2.74%
2024-02-02SaleChief Operating Officer
30,971
0.0506%
$1.36$42,121-2.74%
2024-02-02SaleChief Legal Officer
30,906
0.0509%
$1.37$42,341-2.74%
2023-09-13SaleChief Medical Officer
39,496
0.0732%
$1.27$50,160+10.08%
2023-08-29SaleCEO and President
4,163
0.0075%
$1.30$5,412+3.65%
2023-08-28Saledirector
9,040
0.0172%
$1.26$11,390+12.70%
2023-08-28SaleCEO and President
1,854
0.0035%
$1.26$2,336+12.70%
2023-08-28SaleChief Development Officer
1,854
0.0035%
$1.26$2,336+12.70%
2023-08-28SaleChief Legal Officer
1,854
0.0035%
$1.26$2,336+12.70%
2023-02-03SaleCEO and President
12,286
0.0223%
$1.81$22,238-23.68%

Insider Historical Profitability

<0.0001%
Aquilo Capital, L.P.
5321231
9.7605%
$1.1830
Aquilo Capital Management, LLC10 percent owner
5207796
9.5524%
$1.182111
FORMELA JEAN FRANCOISdirector
2408128
4.4171%
$1.1810<0.0001%
GLAXOSMITHKLINE PLC10 percent owner
1934006
3.5475%
$1.1820<0.0001%
Goyal Vikasdirector
1854006
3.4007%
$1.1810<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Anson Funds Management Lp$6.45M6.953.75M-12.73%-$941,268.280.41
The Vanguard Group$2.84M3.061.65M+0.59%+$16,641.00<0.0001
Alphabet$1.53M1.65889,9790%+$00.01
Murchinson Ltd$1.5M1.62873,910+1.3%+$19,281.200.17
Renaissance Technologies$1.47M1.58854,460+56.08%+$528,149.53<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.